Invention Grant
- Patent Title: Compositions and methods for sensitizing low responsive tumors to cancer therapy
-
Application No.: US15749225Application Date: 2016-12-23
-
Publication No.: US11957732B2Publication Date: 2024-04-16
- Inventor: Raghoottama Pandurangi
- Applicant: Raghoottama Pandurangi
- Applicant Address: US MO Saint Charles
- Assignee: Raghoottama Pandurangi
- Current Assignee: Raghoottama Pandurangi
- Current Assignee Address: US MO Saint Charles
- Agent Raghavan Rajagopalan
- International Application: PCT/US2016/068554 2016.12.23
- International Announcement: WO2017/131911A 2017.08.03
- Date entered country: 2018-01-31
- Main IPC: A61K31/555
- IPC: A61K31/555 ; A61K31/337 ; A61K31/355 ; A61K31/704 ; A61K38/17 ; A61K45/06 ; A61K47/60 ; A61K47/65 ; G01N33/574

Abstract:
The present invention discloses compositions and methods for selectively delivering apoptosis inducing agents to the tumor prior to conventional therapeutic treatment protocol. Specifically, the present invention relates to an ensemble (or ‘AAAPT bioconjugate’) comprising an
apoptogen (A) and a tumor targeting group (T), wherein the apoptogen is either connected directly to the targeting group or optionally attached through an intervening linker (L). The apoptogen may be a small or large molecule that activates apoptosis pathway and causes cell death. The targeting vector may be a small or large molecule that delivers the apoptogen selectively to the tumors. The linker may comprise simple alkylene chain or may contain functional groups that are capable of being cleaved by enzymatic process.
apoptogen (A) and a tumor targeting group (T), wherein the apoptogen is either connected directly to the targeting group or optionally attached through an intervening linker (L). The apoptogen may be a small or large molecule that activates apoptosis pathway and causes cell death. The targeting vector may be a small or large molecule that delivers the apoptogen selectively to the tumors. The linker may comprise simple alkylene chain or may contain functional groups that are capable of being cleaved by enzymatic process.
Public/Granted literature
- US20180318388A1 COMPOSITIONS AND METHODS FOR SENSITIZING LOW RESPONSIVE TUMMORS TO CANCER THERAPY Public/Granted day:2018-11-08
Information query